These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21984751)

  • 1. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.
    Lopez-Atalaya JP; Gervasini C; Mottadelli F; Spena S; Piccione M; Scarano G; Selicorni A; Barco A; Larizza L
    J Med Genet; 2012 Jan; 49(1):66-74. PubMed ID: 21984751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
    Korzus E
    Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
    Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
    Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.
    Viosca J; Lopez-Atalaya JP; Olivares R; Eckner R; Barco A
    Neurobiol Dis; 2010 Jan; 37(1):186-94. PubMed ID: 19822209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability.
    Alari V; Russo S; Terragni B; Ajmone PF; Sironi A; Catusi I; Calzari L; Concolino D; Marotta R; Milani D; Giardino D; Mantegazza M; Gervasini C; Finelli P; Larizza L
    Stem Cell Res; 2018 Jul; 30():130-140. PubMed ID: 29883886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
    Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
    Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rubinstein-Taybi syndrome: clinical and molecular overview.
    Roelfsema JH; Peters DJ
    Expert Rev Mol Med; 2007 Aug; 9(23):1-16. PubMed ID: 17942008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome.
    Di Fede E; Ottaviano E; Grazioli P; Ceccarani C; Galeone A; Parodi C; Colombo EA; Bassanini G; Fazio G; Severgnini M; Milani D; Verduci E; Vaccari T; Massa V; Borghi E; Gervasini C
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and mutational spectrum in Korean patients with Rubinstein-Taybi syndrome: the spectrum of brain MRI abnormalities.
    Lee JS; Byun CK; Kim H; Lim BC; Hwang H; Choi JE; Hwang YS; Seong MW; Park SS; Kim KJ; Chae JH
    Brain Dev; 2015 Apr; 37(4):402-8. PubMed ID: 25108505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.
    Negri G; Milani D; Colapietro P; Forzano F; Della Monica M; Rusconi D; Consonni L; Caffi LG; Finelli P; Scarano G; Magnani C; Selicorni A; Spena S; Larizza L; Gervasini C
    Clin Genet; 2015 Feb; 87(2):148-54. PubMed ID: 24476420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability.
    Valor LM; Pulopulos MM; Jimenez-Minchan M; Olivares R; Lutz B; Barco A
    J Neurosci; 2011 Feb; 31(5):1652-63. PubMed ID: 21289174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients.
    Alari V; Scalmani P; Ajmone PF; Perego S; Avignone S; Catusi I; Lonati PA; Borghi MO; Finelli P; Terragni B; Mantegazza M; Russo S; Larizza L
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
    López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
    BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.
    Fergelot P; Van Belzen M; Van Gils J; Afenjar A; Armour CM; Arveiler B; Beets L; Burglen L; Busa T; Collet M; Deforges J; de Vries BB; Dominguez Garrido E; Dorison N; Dupont J; Francannet C; Garciá-Minaúr S; Gabau Vila E; Gebre-Medhin S; Gener Querol B; Geneviève D; Gérard M; Gervasini CG; Goldenberg A; Josifova D; Lachlan K; Maas S; Maranda B; Moilanen JS; Nordgren A; Parent P; Rankin J; Reardon W; Rio M; Roume J; Shaw A; Smigiel R; Sojo A; Solomon B; Stembalska A; Stumpel C; Suarez F; Terhal P; Thomas S; Touraine R; Verloes A; Vincent-Delorme C; Wincent J; Peters DJ; Bartsch O; Larizza L; Lacombe D; Hennekam RC
    Am J Med Genet A; 2016 Dec; 170(12):3069-3082. PubMed ID: 27648933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients.
    Bentivegna A; Milani D; Gervasini C; Castronovo P; Mottadelli F; Manzini S; Colapietro P; Giordano L; Atzeri F; Divizia MT; Uzielli ML; Neri G; Bedeschi MF; Faravelli F; Selicorni A; Larizza L
    BMC Med Genet; 2006 Oct; 7():77. PubMed ID: 17052327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.
    Bartsch O; Schmidt S; Richter M; Morlot S; Seemanová E; Wiebe G; Rasi S
    Hum Genet; 2005 Sep; 117(5):485-93. PubMed ID: 16021471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.
    Pérez-Grijalba V; García-Oguiza A; López M; Armstrong J; García-Miñaur S; Mesa-Latorre JM; O'Callaghan M; Pineda Marfa M; Ramos-Arroyo MA; Santos-Simarro F; Seidel V; Domínguez-Garrido E
    Mol Genet Genomic Med; 2019 Nov; 7(11):e972. PubMed ID: 31566936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic mechanisms of Rubinstein-Taybi syndrome.
    Park E; Kim Y; Ryu H; Kowall NW; Lee J; Ryu H
    Neuromolecular Med; 2014 Mar; 16(1):16-24. PubMed ID: 24381114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.
    Bartholdi D; Roelfsema JH; Papadia F; Breuning MH; Niedrist D; Hennekam RC; Schinzel A; Peters DJ
    J Med Genet; 2007 May; 44(5):327-33. PubMed ID: 17220215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rubinstein-Taybi syndrome.
    Kosaki R
    Nihon Rinsho; 2017 Mar; 75(3):498-503. PubMed ID: 30566799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.